Taro Okamoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.

Journal: Diabetes, obesity & metabolism

Published: January 19, 2021

A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Journal: Diabetes, obesity & metabolism

Published: October 06, 2020

A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

Journal: Diabetes, obesity & metabolism

Published: September 23, 2020

Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials.

Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials.

Journal: Journal of diabetes investigation

Published: July 30, 2019

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: March 28, 2017

Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes.

Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes.

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: March 07, 2017

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: March 03, 2017

Long-period ocean-bottom motions in the source areas of large subduction earthquakes.

Long-period ocean-bottom motions in the source areas of large subduction earthquakes.

Journal: Scientific reports

Published: August 03, 2015

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes.

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes.

Journal: Journal of diabetes investigation

Published: August 23, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026